Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 177%

Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 177%

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial

Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.

Merck and Moderna say cancer vaccine shows signs of preventing recurrence of melanoma

Moderna stock surges as melanoma vaccine trial shows "landmark moment

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.

MRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

The vaccine reportedly thwarted the cancer's return and spread.

Merck and Moderna say cancer vaccine shows signs of preventing recurrence of melanoma

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients. NBC News health reporter Aria Bendix explains what happens next.

Merck and Moderna say melanoma vaccine shows promise

Promising Results for mRNA Cancer Vaccine from Moderna and Merck

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing skin cancer from returning or spreading in a study of melanoma patients.

STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

Pharmaceutical giants Moderna and Merck said Wednesday that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients. The companies have not published their results in a peer-reviewed journal, nor did they release the new data, saying instead that it will be presented at an upcoming medical meeting and shared with regulators. According to a press release, the mRNA-based vaccine was tested in a late-stage trial involving people who’d already had surgery to remove a melanoma, the deadliest form of skin cancer....